For The Latest Medical News, Health News, Research News, COVID-19 News, Pharma News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Thailand Cannabis News, Epigenetic News, Cancer News, Doctor News, Hospital News, Oral Cancer News

BREAKING NEWS
Nikhil Prasad  Fact checked by:Thailand Medical News Team Feb 06, 2025  2 hours, 41 minutes ago

Mirikizumab Shows Promise for Treating Inflammatory Bowel Disease

2824 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
Mirikizumab Shows Promise for Treating Inflammatory Bowel Disease
Nikhil Prasad  Fact checked by:Thailand Medical News Team Feb 06, 2025  2 hours, 41 minutes ago
Medical News: A New Hope for Patients with Inflammatory Bowel Disease
A new study has shed light on the potential benefits of Mirikizumab, a novel drug designed to help people suffering from inflammatory bowel disease (IBD). Researchers from St George’s University Hospital NHS Foundation Trust-UK, the Institute of Infection and Immunity at St George’s University of London, and the School of Immunology and Microbial Sciences at King’s College London conducted an extensive review on the drug’s effectiveness. Their findings provide crucial insights into the role of Mirikizumab in managing both ulcerative colitis and Crohn’s disease.

Mirikizumab Shows Promise for Treating Inflammatory Bowel Disease

Understanding How Mirikizumab Works
Inflammatory bowel disease includes conditions such as Crohn’s disease and ulcerative colitis, which cause chronic inflammation in the digestive tract. While there are treatments available, many patients struggle with the effectiveness of current options. Mirikizumab is a monoclonal antibody that specifically targets a protein called interleukin-23 (IL-23), which plays a major role in the immune system’s inflammatory response. By blocking IL-23, the drug aims to reduce the inflammation that leads to the painful symptoms of IBD.
 
This Medical News report highlights the results of various clinical trials that tested Mirikizumab’s effectiveness in comparison to existing treatments. The drug was tested in large-scale trials such as the LUCENT and VIVID studies, which evaluated its impact on ulcerative colitis and Crohn’s disease, respectively.
 
Key Findings from the Study
The study demonstrated that Mirikizumab was significantly more effective than a placebo in reducing symptoms and promoting remission in IBD patients. In ulcerative colitis patients, the LUCENT trial showed that Mirikizumab achieved higher rates of clinical remission at week 12 compared to placebo (24.2% versus 13.3%). By week 40, nearly half (49.9%) of patients who continued with Mirikizumab maintained clinical remission, compared to only 25.1% of those receiving a placebo.
 
Additionally, 97.8% of patients who achieved remission were able to stay off corticosteroids, which are often used as a short-term treatment for flare-ups but have serious side effects.
 
For Crohn’s disease, the VIVID trial compared Mirikizumab with both a placebo and ustekinumab, another drug used to treat IBD. At week 12, 45.4% of Mirikizumab-treated patients achieved a clinical response, compared to just 19.6% in the placebo group. The study also showed that the drug provided significant reductions in abdominal pain, stool frequency, and inflammatory markers such as C-reactive protein (CRP) and fecal calprotectin, which indicate disease activity.
 
How Mirikizumab Compares to Other Treatments
Mirikizumab was compared with ustekinumab, a drug that inhibits both IL-12 and IL-23, and was found to be similarly effective in clinica l remission rates. However, it showed higher numerical response rates in endoscopic healing, meaning it might be a better option for patients whose main concern is visible healing of the intestinal lining.
 
One of the most promising aspects of Mirikizumab is its ability to help patients who have previously failed other treatments, such as anti-TNF drugs and integrin inhibitors. The study showed that patients who did not respond to these traditional treatments still had a high likelihood of achieving remission with Mirikizumab.
 
Safety and Side Effects
Like all medications, Mirikizumab comes with potential side effects. The study found that most patients tolerated the drug well, with only a small percentage experiencing serious adverse effects. Common side effects included mild infections, headaches, and injection site reactions. Serious adverse events such as opportunistic infections, liver enzyme elevations, and rare cardiovascular issues were reported but occurred at low rates comparable to other advanced therapies. Importantly, only 2% of patients developed high levels of antibodies against the drug, which could potentially reduce its effectiveness.
 
Conclusion
Mirikizumab represents a significant advancement in the treatment of inflammatory bowel disease, particularly for patients who have struggled with existing therapies. The drug has shown strong results in clinical trials, offering higher rates of remission and reduced inflammation compared to placebo and even some existing treatments. Its ability to help patients who have failed previous therapies makes it a valuable addition to the treatment landscape. While further research is needed to establish its long-term effectiveness and cost-efficiency, the findings so far are promising. Patients and healthcare providers now have another option to consider when managing the complex and often debilitating effects of inflammatory bowel disease.
 
The study findings were published in the peer-reviewed Journal of Clinical Medicine.
https://www.mdpi.com/2077-0383/14/3/1001
 
For the latest on Inflammatory Bowel Disease, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/chemoprevention-strategies-to-prevent-colorectal-cancer-in-those-with-inflammatory-bowel-disease
 
https://www.thailandmedical.news/news/bile-acids-and-inflammatory-bowel-disease
 
https://www.thailandmedical.news/news/the-probiotic-lacticaseibacillus-casei-ib1-can-help-combat-inflammatory-bowel-disease
 

MOST READ

Dec 11, 2024  2 months ago
Nikhil Prasad
Nov 26, 2024  2 months ago
Nikhil Prasad
Nov 19, 2024  3 months ago
Nikhil Prasad
Nov 12, 2024  3 months ago
Nikhil Prasad
Nov 05, 2024  3 months ago
Nikhil Prasad
Nov 05, 2024  3 months ago
Nikhil Prasad
Jul 25, 2024  7 months ago
Nikhil Prasad
Jul 24, 2024  7 months ago
Nikhil Prasad